New thinking about beta blockers
For people with high blood pressure, beta blockers are no longer a first line of defense.
Content restricted. Requires subscription
Month: March 2015
Can you put off that knee surgery?
Surgery is not always necessary to relieve knee pain. The first line of treatment is three months of physical therapy.
Content restricted. Requires subscription
Want to get healthier? Get your partner involved!
It appears that men and women are much more likely to make positive changes in health behavior if their partners also change their health behavior during the same period.
Content restricted. Requires subscription
Best tips to stay on your medication and stay healthy
Nonadherence to medication regimens is a major public health problem. Strategies to solve it include finding more affordable medications and implementing ways to remember to take them.
Content restricted. Requires subscription
Bone Marrow Transplant
Content restricted. Requires subscription
Mitral Valve Prolapse
Content restricted. Requires subscription
Pneumonia
Content restricted. Requires subscription
2015 Annual Report on Prostate Diseases
Content restricted. Requires subscription
A guide to coping with Alzheimer’s Disease
Content restricted. Requires subscription
New Drugs Lower LDL, May Protect Heart
A new type of drug lowers cholesterol and may also reduce heart attack and stroke rates, study results show. The 2 new studies look at drugs known as monoclonal antibodies. Both of the study drugs work by shutting down a protein in the liver. The larger study included 4,465 people. They were randomly divided into 2 groups. One group got injections of evolocumab every 2 weeks or every month. People also got standard treatment to lower LDL (“bad cholesterol”). Usually this was a statin drug. The other group got standard treatment only. In the next year, LDL fell 61% more in the evolocumab group than in the standard-treatment group. About 2% of the statin-only group died or had a heart attack, stroke or related event during the study. The rate was 1% in the group taking the new drug. The other study included 2,341 people.
Content restricted. Requires subscription